Trends in Gram-negative bloodstream infection, antimicrobial use and antimicrobial resistance in Northern Ireland


Document Version:
Other version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2018 The Authors.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Trends in Gram-negative bloodstream infection, antimicrobial use and antimicrobial resistance in Northern Ireland

Christopher Nugent, Lynsey Patterson, Declan T. Bradley
Health Protection, Public Health Agency, Belfast, Northern Ireland
Email: chris.nugent@hscni.net

Introduction:
Antimicrobial resistance (AMR) is a present and growing threat to global human health. Gram-negative organisms present a particular challenge due to their ability to develop resistance, while the inappropriate and overuse of antibiotics further accelerates the AMR process. The Northern Ireland (NI) Department of Health, Social Services and Public Safety aimed to ‘establish and maintain systems to monitor antimicrobial usage and surveillance of resistance’ (DHSSPSNI, 2012). The selected results outlined in this poster are the product of that system. Full results are available at: [http://pha.site/AMR2017](http://pha.site/AMR2017)

Methods:

### Trust microbiology labs (x 5) test for GNBs

2009-2016 period

### +VEs voluntarily reported to CoSurv

### Public Health Agency HCAI team

Antibiotic susceptibility testing. Reported to PHA as:
- **Susceptible (S):** growth inhibited in vitro by a concentration of the drug associated with a high likelihood of therapeutic success.
- **Indeterminate (I):** concentration required to inhibit growth in vitro associated with uncertain therapeutic outcome at standard doses.
- **Resistant (R):** concentration required to inhibit growth in vitro associated with a high likelihood of therapeutic failure.

*I and R grouped together as ‘Non-Susceptible’ for reporting purposes.

Results:

#### Resistance:

<table>
<thead>
<tr>
<th>Organism</th>
<th>Year</th>
<th>Percent Resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. coli</td>
<td>2009</td>
<td>20%</td>
</tr>
<tr>
<td>K. pneumoniae</td>
<td>2009</td>
<td>15%</td>
</tr>
<tr>
<td>Pseudomonas Spp.</td>
<td>2009</td>
<td>5%</td>
</tr>
</tbody>
</table>

#### Consumption:

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>2009-2016 Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbenemems</td>
<td></td>
</tr>
<tr>
<td>Piperacillin/tazobactum</td>
<td></td>
</tr>
<tr>
<td>Colistin</td>
<td></td>
</tr>
<tr>
<td>Penicillins</td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td></td>
</tr>
</tbody>
</table>

Conclusions:

- There has been an increasing incidence of gram-negative bloodstream infections and a small rise in the proportion resistant to selected antibiotics.
- Rates of antibiotic consumption are stable but substantially higher than other parts of the UK.
- We have limited information about who is receiving antibiotics and who is prescribing them.

Recommendations:

- Further investigation is needed to identify who is receiving and prescribing antibiotics in Northern Ireland.
- Availability of timely, detailed intelligence for practitioners/managers should help target efforts to reduce consumption and inappropriate antibiotic use.